Scinai Immunotherapeutics
SCNI
12 hedge funds and large institutions have $789K invested in Scinai Immunotherapeutics in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
41% more capital invested
Capital invested by funds: $560K → $789K (+$229K)
0.44% more ownership
Funds ownership: 1.38% → 1.82% (+0.44%)
8% less funds holding
Funds holding: 13 → 12 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$103K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$101K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$66K |
| 4 |
TPWA
TRUE Private Wealth Advisors
Salem,
Oregon
|
+$39.2K |
| 5 |
State Street
Boston,
Massachusetts
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$78K |
| 2 |
VF
Virtu Financial
New York
|
-$49K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$40K |
| 4 |
Morgan Stanley
New York
|
-$4.13K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
SCNI Hedge Fund Activity: Q4 2021 in Review
12 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2021, worth a combined $789K — up 41% from $560K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SCNI and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Envestnet Asset Management, opening a new position worth an estimated $103K. The largest seller was HRT Financial, exiting entirely with an estimated $78K sold.
- 12 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2021, down from 13 in Q3 2021.
- Funds reported $789K of Scinai Immunotherapeutics stock for Q4 2021, up 41% quarter-over-quarter.
- 3 funds opened new Scinai Immunotherapeutics positions in Q4 2021 and 4 closed out, a net change of -1 holder.
- The largest Scinai Immunotherapeutics buyer in Q4 2021 was Envestnet Asset Management, an estimated $103K added.
- The largest Scinai Immunotherapeutics seller in Q4 2021 was HRT Financial, an estimated $78K sold.
Based on aggregated 13F filings for Q4 2021.